Renamic Neo
Biotronik, Inc. · Decision date Apr 24, 2026
What did the FDA approve?
FDA records P070008/S175 as a supplement to PMA P070008, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 24, 2026.
FDA approval order statement
approval for display and programming head updates to Renamic Neo programmer
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 24, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P070008/S175
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik, Inc.
- Product code
- NKE
- Decision code
- APPR
- Decision date
- Apr 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pulse generator, pacemaker, implantable, with cardiac resynchronization (CRT-P).
- Applicant
- Biotronik, Inc.
- Product code
- NKE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P070008. Subsequent supplements may change the device or its indications.
FDA decision timeline
P070008 · Original PMA
STRATOS LV CRT-P AND STRATOS LV-T CRT-P, COROX OTW BP LEAD AND COROX OTW-S BP LEAD
P070008/S169 · Related supplement
Edora 8 HF-T QP (407137); Edora 8 HF-T (407138); Evity 8 HF-T QP (407139); Evity 8 HF-T (407140); Enitra 8 HF-T QP (4071
P070008/S170 · Related supplement
Edora 8 HF-T QP 407137; Edora 8 HF-T 407138; Evity 8 HF-T QP 407139; Evity 8 HF-T 407140; Enitra 8 HF-T QP 407141; Enitr
P070008/S171 · Related supplement
Edora 8 HF-T QP 407137 Edora 8 HF-T 407138 Evity 8 HF-T QP 407139 Evity 8 HF-T 407140 Enitra 8 HF-T QP 407141 Enitra 8 H
P070008/S167 · Related supplement
Edora 8 HF-T QP; Edora 8 HF-T; Evity 8 HF-T QP; Evity 8 HF-T; Enitra 8 HF-T QP; Enitra 8 HF-T; Enticos 8 HF-T QP; Entico
P070008/S173 · Related supplement
Sentus ProMRI OTW QP S-75; Sentus ProMRI OTW QP S-85; Sentus ProMRI OTW QP S-95; Sentus ProMRI OTW QP L-75; Sentus ProMR
P070008/S175 received
Application receipt date recorded by FDA.
P070008/S174 · Related supplement
STRATOS LV CRT-P AND STRATOS LV-T CRT-P, COROX OTW BP LEAD AND COROX OTW-S BP LEAD
P070008/S176 · Related supplement
Edora 8 HF-T QP (407137); Edora 8 HF-T (407138); Evity 8 HF-T QP (407139); Evity 8 HF-T (407140); Enitra 8 HF-T QP (4071
P070008/S175 · FDA decision
Real-Time Process
P070008/S178 · Related supplement
Edora 8 HF-T QP, Edora 8 HF-T, Evity 8 HF-T QP, Evity 8 HF-T, Enitra 8 HF-T QP, Enitra 8 HF-T, Amvia Sky HF-T, Amvia Sky
P070008/S179 · Related supplement
PSW 2601.U, NEO 2601.U
P070008/S172 · Related supplement
Edora 8 HF-T QP 407137 Edora 8 HF-T 407138 Evity 8 HF-T QP 407139 Evity 8 HF-T 407140 Enitra 8 HF-T QP 407141 Enitra 8 H
P070008/S182 · Related supplement
Edora 8 HF-T QP Edora 8 HF-T Evity 8 HF-T QP Evity 8 HF-T Enitra 8 HF-T QP Enitra 8 HF-T Enticos 8 HF-T QP Enticos 8 HF-
P070008/S181 · Related supplement
Edora 8 HF-T QP 407137; Edora 8 HF-T 407138; Evity 8 HF-T QP 407139; Evity 8 HF-T 407140; Enitra 8 HF-T QP 407141; Enitr
P070008/S183 · Related supplement
Edora 8 HF-T QP, Edora 8 HF-T, Evity 8 HF-T QP, Evity 8 HF-T, Enitra 8 HF-T QP, Enitra 8 HF-T
P070008/S177 · Related supplement
BIOexpress
P070008/S184 · Related supplement
Sentus ProMRI OTW QP S-75, Sentus ProMRI OTW QP S-85, Sentus ProMRI OTW QP S-95, Sentus ProMRI OTW QP L-75, Sentus ProMR
Timeline entries are records held by MedtechLedger for P070008. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P070008
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA approval | May 12, 2008 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 11, 2025 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 15, 2025 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 16, 2025 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 24, 2025 | FDA | |
| Biotronik, Inc. | PMA supplement | Dec 10, 2025 | FDA | |
| Biotronik, Inc. | PMA supplement | Feb 3, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Mar 5, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | May 7, 2026 | FDA | |
PSW 2601.U, NEO 2601.UP070008/S179 | Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 5, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
BIOexpressP070008/S177 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA |
Explore the linked device profile
Other records with product code NKE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Guidant Corp. | PMA supplement | Oct 3, 2026 | FDA | |
| Guidant Corp. | PMA supplement | Jul 23, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Jul 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P070008/S175
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





